Advance ZincTek warns fixed costs will amplify sunscreen sales downturn
Advance ZincTek expects first-half FY27 revenue to fall 11% to 18%, despite a partial recovery in Australian sunscreen sales after a sharp first-quarter decline. The company is also preparing potential legal action against MooGoo and planning another 3-cent capital reduction in 2027.
- First-half FY27 revenue forecast to fall 11% to 18%
- First-quarter sunscreen sales improved from down 71% to down 20% by late October
- Potential Federal Court claim against MooGoo remains unfiled and unquantified
- Further 3-cent capital reduction planned for 2027
- Fourteen US shipments were unaffected by the FDA Import Alert
Add us as a preferred source on Google
First-half revenue faces double-digit decline
Advance ZincTek Ltd (ASX:ANO) has put a number on the damage from its Australian sunscreen setback, forecasting first-half FY27 sales revenue to fall between 11% and 18%. Profit will also be negatively affected because fixed overheads are expected to remain stable while sales weaken.
The company attributed the decline primarily to lower Australian sales involving MooGoo and an ABC television report. That follows a first-quarter collapse in sunscreen sales, which ANO previously said was linked to customer cancellations after media coverage and regulatory involvement over product labelling. By the end of October, the fall had narrowed to 20% from 71% in the first quarter, according to the update. The recovery is material, but it has not yet erased the first-half revenue shortfall.
MooGoo claim remains at preparation stage
ANO said it is preparing a claim against MooGoo over what it describes as misleading public statements about the zinc used in Veganic sunscreen products. Legal counsel has been engaged, but proceedings had not commenced at the date of the update and the potential quantum was still being finalised. The company said proceedings are expected to begin in the near future.
The legal strategy follows the 71% first-quarter sales decline previously disclosed by ANO, which the company linked to customer cancellations after the December 2025 ABC coverage and subsequent TGA involvement. Separately, Veganic SKN Limited has lodged a Federal Court matter seeking orders that certain federal determinations allowing 4-MBC, homosalate and trolamine salicylate as permissible ingredients be declared invalid or quashed. The filing does not state that the court has granted those orders.
Capital return and US shipments provide partial offsets
The board is planning another capital reduction of 3 cents per share in 2027, with further information promised to shareholders within two months. That would follow the earlier 2-cent capital return, which distributed approximately $1.252 million to shareholders in February 2026. The terms and timing of the new reduction have not yet been provided.
ANO also said 14 shipments to the United States had been unaffected by the FDA Import Alert. That confirmation offers some reassurance for the US business, although the update does not quantify the shipments' value or provide a broader assessment of the alert's status. The company reported FY26 sales of $13.111 million, up 12.64%, before the current Australian revenue disruption emerged.
Regulatory changes sharpen the product challenge
The update sets out a widening regulatory debate around homosalate and 4-MBC, two UV filters used in sunscreen formulations. In Australia, homosalate remains permitted at up to 15% by weight, but the TGA's proposed restrictions include materially lower concentration limits and an interim decision is due by the end of 2026. For 4-MBC, the TGA's July 2026 review recommended restrictions, with options ranging from a 0.39% limit to a full ban and an interim decision expected in 2027.
ANO also highlighted marketing gains that have not yet translated into a comparable increase in commercial orders. Website sessions rose 563% and visitors 688% in the first ten months of 2026, while filtered enquiries increased 44%. Distributor enquiries rose from four to 32, but online orders were up only 3%, to 67. The company plans to keep expanding distributors in Europe, Asia and South America while pursuing a high-purity white sapphire launch and a solid-state battery prototype in 2027.
Bottom Line?
The key test is whether the late-October sunscreen recovery can continue quickly enough to contain the first-half earnings hit before the proposed capital return and legal strategy become more concrete.
Questions in the middle?
- Can ANO convert the late-October sales recovery into a sustained second-half improvement?
- When will the proposed MooGoo proceedings commence, and what damages will ANO ultimately claim?
- How will the TGA decisions on homosalate and 4-MBC affect ANO's formulations, customers and distributor expansion?
Sources
1-
Chair's Presentation to Shareholders (opens in a new tab)Official market announcement. Advance Zinctek Limited · 20 Nov 2026 · advancezinctek.com